Download Free Sample Report

This report contains market size and forecasts of Human Insulin Drugs in global, including the following market information:

• Global Human Insulin Drugs Market Revenue, 2018-2023, 2023-2030, ($ millions)
• Global Human Insulin Drugs Market Sales, 2018-2023, 2023-2030, (K Units)
• Global top five Human Insulin Drugs companies in 2022 (%)

The global Human Insulin Drugs market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Basal or Long-acting Insulins Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Human Insulin Drugs include Novo Nordisk, Sanofi, Eli Lilly, Biocon, Pfizer, Wockhardt, Julphar, Exir and Sedico. etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Insulin Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Insulin Drugs Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Human Insulin Drugs Market Segment Percentages, by Type, 2022 (%)

• Basal or Long-acting Insulins
• Bolus or Fast-acting Insulins
• Traditional Human Insulins
• Combination Insulins
• Biosimilar Insulins

Global Human Insulin Drugs Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Human Insulin Drugs Market Segment Percentages, by Application, 2022 (%)

• Hospital
• Household

Global Human Insulin Drugs Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Human Insulin Drugs Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Human Insulin Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Human Insulin Drugs revenues share in global market, 2022 (%)
• Key companies Human Insulin Drugs sales in global market, 2018-2023 (Estimated), (K Units)
• Key companies Human Insulin Drugs sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Novo Nordisk
• Sanofi
• Eli Lilly
• Biocon
• Pfizer
• Wockhardt
• Julphar
• Exir
• Sedico